Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat severe and life-threatening diseases.
Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 23, 2021 | Series A | $72M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Resilience | — | Series A |